Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Farmaceutica Remedia's Enterprise Value is lei33.4 Mil.
Farmaceutica Remedia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was lei-9.0 Mil. Therefore, Farmaceutica Remedia's EV-to-FCF for today is -3.72.
The historical rank and industry rank for Farmaceutica Remedia's EV-to-FCF or its related term are showing as below:
BSE:RMAH'
s EV-to-FCF Range Over the Past 10 Years
Min: -397.6 Med: 1.84 Max: 66.06
Current: -3.53
During the past 13 years, the highest EV-to-FCF of Farmaceutica Remedia was 66.06. The lowest was -397.60. And the median was 1.84.
BSE:RMAH's EV-to-FCF is ranked worse than 100% of 72
companies
in the Medical Distribution industry
Industry Median: 17.235
vs BSE:RMAH: -3.53
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Farmaceutica Remedia's PE Ratio (TTM) for today is calculated as:
Farmaceutica Remedia's share price for today is lei0.87.
Farmaceutica Remedia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.057.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Farmaceutica Remedia EV-to-FCF Related Terms
Farmaceutica Remedia EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Farmaceutica Remedia's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's EV-to-FCF falls into.
Farmaceutica Remedia's current Enterprise Value is lei33.4 Mil.
Farmaceutica Remedia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei-9.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia (BSE:RMAH) has a EV-to-FCF of -3.72 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Farmaceutica Remedia and its competitors. According to the industry distribution chart, Farmaceutica Remedia ranks #999999 out of 72 companies in the Medical Distribution industry.
Is Farmaceutica Remedia's EV-to-FCF too high?
Farmaceutica Remedia's current EV-to-FCF is -3.72. Based on the distribution chart, Farmaceutica Remedia ranks #999999 out of 72 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Farmaceutica Remedia has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's EV-to-FCF compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #999999 out of 72 companies for EV-to-FCF. This places Farmaceutica Remedia in the lower half of its industry. The industry median EV-to-FCF is 17.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.24, based on 72 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current EV-to-FCF is -3.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.87 — trading 10.1% above its estimated fair value. The current EV-to-FCF is -3.72. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current EV-to-FCF is -3.72 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.87 is trading 10.1% above its estimated GF Value™ of lei0.79.
GuruFocus considers Farmaceutica Remedia to be Fairly Valued.
Key valuation signals for BSE:RMAH:
EV-to-FCF: -3.72
GF Value™: lei0.79 vs. price of lei0.87 (10.1% above fair value)
No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for BSE:RMAH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RMAH has been successfully added to your 
